Categories Earnings, Technology

Marvell Technology (MRVL) Q4 2020 Earnings Snapshot

— Marvell Technology Group (NASDAQ: MRVL) reported fourth quarter 2020 adjusted earnings of $0.17 per share vs. $0.16 expected.

— Revenue grew 8% to $717.7 million vs. $712.95 million expected.

Earnings Update by AlphaStreet

— GAAP net income was $1778 billion, or $2.62 per share vs. a loss of $82.5 million or $0.12 per share in the fourth quarter of 2019.

— For the first quarter of fiscal 2021, revenue is expected to be $780 million +/- 5%.

— 1Q21 GAAP loss is expected to be $(0.20) to $(0.12) per share and non-GAAP income per share is expected to be $0.11 to $0.17 per share.

— On December 6, 2019, the company completed the divestiture of the Wi-Fi Connectivity business to NXP in which Marvell received $1.7 billion in cash proceeds.

— On December 31, 2019, Marvell completed an intra-entity asset transfer of certain of its intellectual property to a subsidiary in Singapore. This restructuring resulted in an income tax benefit of approximately $763 million in Q4 2020.

— MRVL stock jumped more than 10% in the extended hours of trading.

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Also Read:  Qorvo Inc. (QRVO) Q1 2021 Earnings Call Transcript

Most Popular

Baidu (BIDU) Q2 earnings rise unexpectedly; stock falls

https://www.youtube.com/watch?v=50yUaLybUnA&t=667s China-based internet search firm Baidu Inc. (NASDAQ: BIDU) reported financial results for the second quarter of 2020 on Thursday after the market's close. Earnings exceeded analysts’ expectations, but the

Applied Materials (AMAT) tops Q3 2020 targets; provides Q4 outlook

Applied Materials' (NASDAQ: AMAT) earnings and revenue for the third quarter exceeded the market's views. Adjusted EPS of $1.06 and revenue of $4.40 billion in Q3, grew 43% and 23%,

Is Altimmune (ALT) stock a buy right now?

A lot of stocks in the biotech space have skyrocketed this year after their announcements and advances in finding a vaccine or in the treatment of COVID-19. While these companies

Top